hVIVO plc
("hVIVO" or the "Company")
Appointment of Nominated Adviser and Joint Broker
hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.
For further information please contact:
|
hVIVO plc |
+44 (0) 20 7756 1300 |
||
|
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |
|
||
|
|
|
||
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward |
|
||
|
|
|
||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
||
|
James Steel, Dr Christopher Golden |
|
||
|
|
|
||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
|
Anthony Farrell, Niall Gilchrist |
|
||
|
|
|
||
|
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage / |
+44 (0) 20 7933 8780 or hvivo@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / |
||
Notes to Editors
About hVIVO
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
Existing Board - AIM Rule 17 Disclosure
The Company announces the following additional director disclosures pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.
Elaine Sullivan
In addition to the disclosures made in Elaine Sullivan's announcement of appointment on 24 November 2020, the following directorships are disclosed:
|
Company |
Current, or last 5 years |
|
Carrick Therapeutics Limited |
Directorship held in last 5 years, at time of appointment to hVIVO |
Brendan Buckley
The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:
|
Company |
Disclosure |
|
Irish Platform for Patients' Organisations, Science and Industry Company Limited |
Directorship held more than 5 years prior to publication of the Admission Document and therefore should not have been disclosed in the Admission Document |
Cathal Friel
In addition to the disclosures made in the Admission Document dated 9 December 2019, the following directorships are disclosed:
|
Company |
Current, or last 5 years |
|
Amryt Pharma Holdings Limited
|
Directorship held in last 5 years at time of Admission Document publication |
|
Venn Life Sciences Limited Venn Life Sciences (Germany) GmbH Venn Life Sciences (Ireland) Limited Venn Life Sciences (NI) Limited Venn Life Sciences (Australia) Pty Ltd Venn Life Sciences Inc. Venn Life Sciences Legal Representation B.V Venn Life Sciences ED B.V. Venn Life Sciences (France) SAS Venn Life Sciences B.V. |
Current directorship at the time of Admission Document publication |
The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:
|
Company |
Current, or last 5 years |
|
Amryt Pharma plc |
Incorrectly disclosed as a directorship |
|
Fastnet Hydrocarbons Limited Raglan Natural Resources Limited
|
Directorship held in last 5 years at time of Admission Document publication. These directorships were disclosed as current directorships in the Admission Document |
|
Fitzwilliam Place Capital Limited |
Directorship held more than 5 years prior to Admission Document publication and therefore should not have been disclosed in the Admission Document |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
